1. Home
  2. ITOS vs FOF Comparison

ITOS vs FOF Comparison

Compare ITOS & FOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITOS
  • FOF
  • Stock Information
  • Founded
  • ITOS 2011
  • FOF 2006
  • Country
  • ITOS United States
  • FOF United States
  • Employees
  • ITOS N/A
  • FOF N/A
  • Industry
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • FOF Investment Managers
  • Sector
  • ITOS Health Care
  • FOF Finance
  • Exchange
  • ITOS Nasdaq
  • FOF Nasdaq
  • Market Cap
  • ITOS 342.6M
  • FOF 357.1M
  • IPO Year
  • ITOS 2020
  • FOF N/A
  • Fundamental
  • Price
  • ITOS $8.32
  • FOF $13.12
  • Analyst Decision
  • ITOS Strong Buy
  • FOF
  • Analyst Count
  • ITOS 3
  • FOF 0
  • Target Price
  • ITOS $33.67
  • FOF N/A
  • AVG Volume (30 Days)
  • ITOS 543.4K
  • FOF 58.7K
  • Earning Date
  • ITOS 11-12-2024
  • FOF 01-01-0001
  • Dividend Yield
  • ITOS N/A
  • FOF 9.07%
  • EPS Growth
  • ITOS N/A
  • FOF N/A
  • EPS
  • ITOS N/A
  • FOF N/A
  • Revenue
  • ITOS $35,000,000.00
  • FOF N/A
  • Revenue This Year
  • ITOS $271.18
  • FOF N/A
  • Revenue Next Year
  • ITOS N/A
  • FOF N/A
  • P/E Ratio
  • ITOS N/A
  • FOF N/A
  • Revenue Growth
  • ITOS N/A
  • FOF N/A
  • 52 Week Low
  • ITOS $7.54
  • FOF $9.59
  • 52 Week High
  • ITOS $18.75
  • FOF $11.75
  • Technical
  • Relative Strength Index (RSI)
  • ITOS 39.51
  • FOF 59.17
  • Support Level
  • ITOS $7.54
  • FOF $12.70
  • Resistance Level
  • ITOS $8.38
  • FOF $12.84
  • Average True Range (ATR)
  • ITOS 0.53
  • FOF 0.18
  • MACD
  • ITOS 0.01
  • FOF 0.01
  • Stochastic Oscillator
  • ITOS 35.94
  • FOF 74.68

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

About FOF Cohen & Steers Closed-End Opportunity Fund Inc.

Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.

Share on Social Networks: